{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:03:51Z","timestamp":1792854231412,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0412"],"award-info":[{"award-number":["W81XWH-14-1-0412"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0583-4","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:01:40Z","timestamp":1503446500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics"],"prefix":"10.1186","volume":"36","author":[{"given":"Liwei","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"583_CR2","doi-asserted-by":"publisher","first-page":"v129","DOI":"10.1093\/annonc\/mdq174","volume":"21","author":"A Horwich","year":"2010","unstructured":"Horwich A, Parker C, Bangma C, Kataja V, Group EGW. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v129\u201333.","journal-title":"Ann Oncol"},{"key":"583_CR3","first-page":"1","volume":"14","author":"H Lepor","year":"2012","unstructured":"Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol. 2012;14:1\u201312.","journal-title":"Rev Urol"},{"key":"583_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature12624","volume":"501","author":"CE Meacham","year":"2013","unstructured":"Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328\u201337.","journal-title":"Nature"},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0303-7207(02)00263-0","volume":"197","author":"Z Culig","year":"2002","unstructured":"Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol. 2002;197:231\u20138.","journal-title":"Mol Cell Endocrinol"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s002400000111","volume":"28","author":"Z Culig","year":"2000","unstructured":"Culig Z, Hobisch A, Bartsch G, Klocker H. Androgen receptor\u2013an update of mechanisms of action in prostate cancer. Urol Res. 2000;28:211\u20139.","journal-title":"Urol Res"},{"key":"583_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279\u201390.","journal-title":"Oncogene"},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK\u2013RAS\u2013RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103\u201319.","journal-title":"Expert Opin Ther Targets"},{"key":"583_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/pros.2990200407","volume":"20","author":"JW Moul","year":"1992","unstructured":"Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH. Infrequent RAS oncogene mutations in human prostate cancer. Prostate. 1992;20:327\u201338.","journal-title":"Prostate"},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1128\/MCB.00955-07","volume":"27","author":"J Yin","year":"2007","unstructured":"Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, Kelly K. Activation of the RalGEF\/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007;27:7538\u201350.","journal-title":"Mol Cell Biol"},{"key":"583_CR12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.4155\/fmc.11.121","volume":"3","author":"AT Baines","year":"2011","unstructured":"Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3:1787\u2013808.","journal-title":"Future Med Chem"},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00280-007-0451-6","volume":"61","author":"R Haklai","year":"2008","unstructured":"Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol. 2008;61:89\u201396.","journal-title":"Cancer Chemother Pharmacol"},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","volume":"30","author":"D Laheru","year":"2012","unstructured":"Laheru D, Shah P, Rajeshkumar N, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Investig New Drugs. 2012;30:2391\u20139.","journal-title":"Investig New Drugs"},{"key":"583_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.pharmthera.2016.03.010","volume":"162","author":"SY Quah","year":"2016","unstructured":"Quah SY, Tan MS, Teh YH, Stanslas J. Pharmacological modulation of oncogenic Ras by natural products and their derivatives: renewed hope in the discovery of novel anti-Ras drugs. Pharmacol Ther. 2016;162:35\u201357.","journal-title":"Pharmacol Ther"},{"key":"583_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/pros.10336","volume":"58","author":"RA McPherson","year":"2004","unstructured":"McPherson RA, Conaway MC, Gregory CW, Yue W, Santen RJ. The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate. 2004;58:325\u201334.","journal-title":"Prostate"},{"key":"583_CR18","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/0008-5472.CAN-06-4287","volume":"67","author":"R Blum","year":"2007","unstructured":"Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007;67:3320\u20138.","journal-title":"Cancer Res"},{"key":"583_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/1476-4598-9-256","volume":"9","author":"N Charette","year":"2010","unstructured":"Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, St\u00e4rkel P. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010;9:256.","journal-title":"Mol Cancer"},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrm1910","volume":"7","author":"C D'Souza-Schorey","year":"2006","unstructured":"D'Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol. 2006;7:347\u201358.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"583_CR21","doi-asserted-by":"publisher","first-page":"58111","DOI":"10.18632\/oncotarget.11185","volume":"7","author":"X Xie","year":"2016","unstructured":"Xie X, Tang S-C, Cai Y, Pi W, Deng L, Wu G, Chavanieu A, Teng Y. Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor. Oncotarget. 2016;7:58111\u201320.","journal-title":"Oncotarget"},{"key":"583_CR22","doi-asserted-by":"publisher","first-page":"41573","DOI":"10.1074\/jbc.R300026200","volume":"278","author":"JG Donaldson","year":"2003","unstructured":"Donaldson JG. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J Biol Chem. 2003;278:41573\u20136.","journal-title":"J Biol Chem"},{"key":"583_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/mc.20766","volume":"50","author":"IH Koumakpayi","year":"2011","unstructured":"Koumakpayi IH, Le Page C, Delvoye N, Saad F, Mes-Masson AM. Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Mol Carcinog. 2011;50:901\u201312.","journal-title":"Mol Carcinog"},{"key":"583_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s40064-015-1136-y","volume":"4","author":"C Morgan","year":"2015","unstructured":"Morgan C, Lewis PD, Hopkins L, Burnell S, Kynaston H, Doak SH. Increased expression of ARF GTPases in prostate cancer tissue. SpringerPlus. 2015;4:342.","journal-title":"SpringerPlus"},{"key":"583_CR25","doi-asserted-by":"publisher","first-page":"39834","DOI":"10.18632\/oncotarget.9405","volume":"7","author":"JE Davis","year":"2016","unstructured":"Davis JE, Xie X, Guo J, Huang W, Chu W-M, Huang S, Teng Y, Wu G. ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling. Oncotarget. 2016;7:39834\u201345.","journal-title":"Oncotarget"},{"key":"583_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1097-2765(03)00475-1","volume":"12","author":"E Mossessova","year":"2003","unstructured":"Mossessova E, Corpina RA, Goldberg J. Crystal structure of ARF1\u2022 Sec7 complexed with Brefeldin a and its implications for the guanine nucleotide exchange mechanism. Mol Cell. 2003;12:1403\u201311.","journal-title":"Mol Cell"},{"key":"583_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5497\/wjp.v1.i4.55","volume":"1","author":"SG Bourgoin","year":"2012","unstructured":"Bourgoin SG, El Azreq M-A. Small inhibitors of ADP-ribosylation factor activation and function in mammalian cells. World J Pharmacol. 2012;1:55\u201364.","journal-title":"World J Pharmacol"},{"key":"583_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/onc.2015.86","volume":"35","author":"Y Teng","year":"2016","unstructured":"Teng Y, Ren X, Li H, Shull A, Kim J, Cowell JK. Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein. Oncogene. 2016;35:333\u201343.","journal-title":"Oncogene"},{"key":"583_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1186\/s12885-016-2851-7","volume":"16","author":"L Shi","year":"2016","unstructured":"Shi L, Zhang W, Zou F, Mei L, Wu G, Teng Y. KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma. BMC Cancer. 2016;16:815\u201324.","journal-title":"BMC Cancer"},{"key":"583_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","volume":"36","author":"L Gao","year":"2017","unstructured":"Gao L, Wang X, Tang Y, Huang S, Hu C-AA, Teng Y. FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017;36:8\u201317.","journal-title":"J Exp Clin Cancer Res"},{"key":"583_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-017-0485-0","volume":"10","author":"Y Teng","year":"2016","unstructured":"Teng Y, Cai Y, Pi W, Gao L, Shay C. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. J Hematol Oncol. 2016;10:118.","journal-title":"J Hematol Oncol"},{"key":"583_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","volume":"439","author":"B Rotblat","year":"2008","unstructured":"Rotblat B, Ehrlich M, Haklai R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467\u201389.","journal-title":"Methods Enzymol"},{"key":"583_CR33","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065\u201374.","journal-title":"J Clin Invest"},{"key":"583_CR34","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-12-0563","volume":"18","author":"PJ Roberts","year":"2012","unstructured":"Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J. Combined PI3K\/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012;18:5290\u2013303.","journal-title":"Clin Cancer Res"},{"key":"583_CR35","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228\u201337.","journal-title":"Cancer Res"},{"key":"583_CR36","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1096\/fj.06-7859rev","volume":"22","author":"MR Junttila","year":"2008","unstructured":"Junttila MR, Li S-P, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 2008;22:954\u201365.","journal-title":"FASEB J"},{"key":"583_CR37","first-page":"3051","volume":"118","author":"CW Kinkade","year":"2008","unstructured":"Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C. Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008;118:3051\u201364.","journal-title":"J Clin Invest"},{"key":"583_CR38","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2174\/156800910793358005","volume":"10","author":"HC Whitaker","year":"2010","unstructured":"Whitaker HC, Neal DE. RAS pathways in prostate cancer-mediators of hormone resistance? Curr Cancer Drug Targets. 2010;10:834\u20139.","journal-title":"Curr Cancer Drug Targets"},{"key":"583_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","volume":"15","author":"T Badar","year":"2015","unstructured":"Badar T, Cortes JE, Ravandi F, O'brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin. Lymphoma Myeloma Leuk. 2015;15:433\u2013438. e432.","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"583_CR40","doi-asserted-by":"publisher","first-page":"10370","DOI":"10.1073\/pnas.0700773104","volume":"104","author":"J Viaud","year":"2007","unstructured":"Viaud J, Zeghouf M, Barelli H, Zeeh J-C, Padilla A, Guibert B, Chardin P, Royer CA, Cherfils J, Chavanieu A. Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein\u2013protein complexes. Proc Natl Acad Sci. 2007;104:10370\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"583_CR41","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1074\/jbc.M111.316125","volume":"287","author":"Y Ohashi","year":"2012","unstructured":"Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. J Biol Chem. 2012;287:3885\u201397.","journal-title":"J Biol Chem"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-017-0583-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0583-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:21:30Z","timestamp":1589548890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0583-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0583-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Augusta University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"112"}}